Shareable Research Card

IMRN - Immuron Ltd Liabilities

This metric view shows IMRN - Immuron Ltd liabilities history from SEC company facts.

Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.

Context
Latest reported period: Q2 2025
Latest reported value
A$2,060,787

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.

Return Loop

Why revisit this metric view

This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.

Latest source-backed update
Latest period end 30 Jun 2025
Why come back
Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
  • Current latest reported period: Q2 2025.
  • Latest reported value on this page: A$2,060,787.
  • Save this filer if you want to compare the next reported value with this history.

Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.

Latest update

Latest update for Liabilities

New fact period available

Latest reported liabilities: A$2,060,787. Open the source-backed page to compare this metric with the newest filing-backed context.

Update date

30 Jun 2025

Page type

Metric history

Latest period

Q2 2025

SEC-backed company facts were refreshed from filings filed on 25 Sep 2025.

Benchmark Context

How Liabilities compares with peers

Immuron Ltd sits in the bottom quarter of the current liabilities sample.

Compared with

Compared with 19 companies reporting liabilities in AUD. This keeps the comparison on the same metric and unit family.

Why this is notable

This is about 0.2x the current sample midpoint. Liabilities is down about 27% versus the comparable prior period.

  • Visible rows currently span reported period ends from 30 Jun 2019 to 30 Jun 2025.
  • Nearby companies in this sample: Nova Minerals Ltd.
  • Current sample position: rank #19 of 19 comparable companies.
  • Peer rows use the latest valid value per company for this exact metric and compatible units.

Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.

Save this filer page

Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.

Financial Metric Page

Immuron Ltd: Liabilities

Latest period: Q2 2025. Period end: 30 Jun 2025. Units: AUD and USD. Frequency: quarterly.

Liabilities is an SEC-reported metric from company XBRL facts.

What This Metric Tells You

  • Shows the reported level of liabilities over 30 Jun 2016 - 30 Jun 2025.
  • Includes year-over-year change points to highlight acceleration or slowdown.
  • Built from 16 SEC fact rows for this metric and issuer.

How To Read This Chart

  • Start with the latest point, then compare it with the prior periods to see direction.
  • Use quarterly sequence to compare like-for-like periods.
  • Use YoY change bars to separate growth from contraction across matching periods.

Compare This Metric Across Companies

Compare latest available Liabilities levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.

Immuron Ltd appears at rank #19 in the latest comparison sample.

Rank Company Latest value Reported period Next step
1 WESTPAC BANKING CORP (webnf) A$1,005,492,000,000 Instant - 30 Sep 2024 Open WESTPAC BANKING CORP Liabilities
2 Telix Pharmaceuticals Ltd (tlx) A$948,218,000 Instant - 31 Dec 2024 Open Telix Pharmaceuticals Ltd Liabilities
3 Carbon Revolution Public Ltd Co (crevf) A$251,862,000 Instant - 30 Jun 2024 Open Carbon Revolution Public Ltd Co Liabilities
4 Elevra Lithium Ltd (elvr) A$177,268,000 Instant - 30 Jun 2025 Open Elevra Lithium Ltd Liabilities
5 NOVONIX Ltd (nvx) A$75,218,083 Instant - 30 Jun 2022 Open NOVONIX Ltd Liabilities
6 KAZIA THERAPEUTICS LTD (kzia) A$31,602,000 Instant - 30 Jun 2024 Open KAZIA THERAPEUTICS LTD Liabilities

Metric Details

Metric
Liabilities (Liabilities)
Taxonomy
ifrs-full
Units tracked
AUD and USD
Frequency coverage
quarterly
History range
30 Jun 2016 - 30 Jun 2025
Facts on this page
16
Metric-level SEC endpoint
Open SEC company concept

Chart Context

Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.

Liabilities, Quarterly (AUD)
Liabilities, YoY Quarterly Change (%)
Liabilities, Quarterly (USD)
Liabilities, YoY Quarterly Change (%)

Immuron Ltd Quarterly Liabilities (AUD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 A$2,060,787 -A$779,738 -27% 30 Jun 2025 20-F 25 Sep 2025 2025 FY
Q2 2024 A$2,840,525 +A$469,179 +20% 30 Jun 2024 20-F 25 Sep 2025 2025 FY
Q2 2023 A$2,371,346 +A$692,923 +41% 30 Jun 2023 20-F 25 Sep 2025 2025 FY
Q2 2022 A$1,678,423 +A$520,374 +45% 30 Jun 2022 20-F 01 Oct 2024 2024 FY
Q2 2021 A$1,158,049 +A$599,799 +107% 30 Jun 2021 20-F 28 Sep 2023 2023 FY
Q2 2020 A$558,250 -A$652,261 -54% 30 Jun 2020 20-F 09 Sep 2022 2022 FY
Q2 2019 A$1,210,511 +A$407,173 +51% 30 Jun 2019 20-F 29 Oct 2021 2021 FY
Q2 2018 A$803,338 -A$908,227 -53% 30 Jun 2018 20-F 28 Oct 2020 2020 FY
Q2 2017 A$1,711,565 -A$2,175,356 -56% 30 Jun 2017 20-F 28 Oct 2019 2019 FY
Q2 2016 A$3,886,921 30 Jun 2016 20-F 31 Oct 2018 2018 FY

Immuron Ltd Quarterly Liabilities (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2023 $2,356,201 +$519,676 +28% 31 Dec 2023 6-K/A 28 May 2024 2024 Q2
Q2 2023 $2,371,346 30 Jun 2023 6-K/A 28 May 2024 2024 Q2
Q4 2022 $1,836,525 31 Dec 2022 6-K/A 28 May 2024 2024 Q2
Q4 2019 $1,521,687 +$1,000,453 +192% 31 Dec 2019 6-K/A 19 Jun 2020 2019 Q2
Q2 2019 $1,210,511 30 Jun 2019 6-K/A 19 Jun 2020 2019 Q2
Q4 2018 $521,234 31 Dec 2018 6-K/A 19 Jun 2020 2019 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .